secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celularity Inc (CELU)
CIK:        0001752828
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001493152-24-041330
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celularity acquires Rebound placental matrix product from Sequence LifeScience for $5.5M
--------------------------------------------------------------------------------

- Total consideration $5.5M: $1M upfront cash, up to $4M monthly milestone payments (20% of net sales), and $500K credit.
- Exclusive supply agreement with Sequence for min 6 months; Celularity intends to transfer manufacturing in-house.
- H1 2024 biomaterial sales >$24M, exceeding full year 2023; Rebound expected to contribute in Q4 2024.
- Rebound is full-thickness placental-derived allograft matrix for wound care and soft tissue repair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1752828/000149315224041330/0001493152-24-041330-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1752828/000149315224041330/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-041330

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer